October:‌ The company was re-evaluated and recognized as an ‌Innovative SME‌.

October:‌ Re-recognized as a ‌"Specialized, Refined, Unique, and Innovative" (SRUI) SME‌.

September:‌ Re-recognized as a ‌Science and Technology SME.

September:‌ Unveiled its weight-loss product,5. FLOBALTM PRESSED CANDY, for the first time at the inaugural launch conference of the Guizhou Chamber of Commerce.

April:‌ At the launch ceremony of the ‌"Win-Win Enterprise Partnership Plan,"‌ DiQi Pharmaceuticals, as one of the first signing enterprises, formally signed a strategic cooperation agreement with ‌Bank of Guangzhou‌.

December:‌ Recognized as a ‌High-Tech Enterprise‌ for the ‌fourth‌ time.

June:‌ DiQi's first proprietary drug, ‌Dileton® Pregabalin Orally Disintegrating Tablets‌, received marketing approval.

January:‌ Awarded the title of ‌2023 Guangzhou "Leading Enterprise for Intended Listing"‌.

November:‌ Listed among the ‌inaugural Top 100 Rising Enterprises in Guangzhou‌.

January:‌ Recognized as a ‌Guangdong Province 2022 "Specialized, Refined, Unique, and Innovative" (SRUI) SME‌ and an ‌Innovative SME‌.

‌October:‌ Passed an ‌unannounced GMP inspection‌ by the Guangdong Provincial Medical Products Administration.

June:‌ Entered the ‌Science and Technology SME database‌.

April:‌ Obtained the ‌manufacturing license (Type B) for Pregabalin Orally Disintegrating Tablets‌.

March:‌ Passed the ‌on-site inspection and acceptance testing‌ for Marketing Authorization Holder (MAH) status by the Guangdong Provincial Medical Products Administration.

December:‌ Recognized as a ‌High-Tech Enterprise‌ for the ‌third‌ time.

June:‌ Again received the title of ‌Guangdong Province "Contract-Honoring and Creditworthy Enterprise"‌.

December:‌ Awarded the title of ‌Pioneering Enterprise in the 3rd GBA Biotech Innovation 50‌ (Greater Bay Area).

December:‌ Passed the ‌dynamic evaluation of the 2020 Guangdong Provincial Engineering Technology Research Center‌.

July:‌ The ‌GuangZhou DiQi Pharmaceuticals Co., Ltd. - Guangdong Province Joint Postgraduate Training Base‌ was officially established.

June:‌ Received the title of ‌Guangdong Province "Contract-Honoring and Creditworthy Enterprise"‌.

March:‌ Rated as a ‌Guangzhou "Two Highs, Four News" Enterprise‌ (high-growth, high-tech; new technologies, new industries, new business models, new formats).

December:‌ Signed a strategic cooperation agreement, officially initiating a new business collaboration model!

October:‌ Awarded the title of ‌Pioneering Enterprise in the 2nd GBA Biotech Innovation 50‌.

July:‌ The BIO-island site hosted an on-site inspection by the National Medical Products Administration and successfully passed.

May:‌ Rated and entered into the ‌Science and Technology SME database‌.

December:‌ Recognized as a ‌2018 Guangdong Provincial Innovative Pilot Enterprise‌.

December:‌ Recognized as a ‌2018 Guangzhou Development District Gazelle Enterprise‌.

December:‌ Obtained the ‌Intellectual Property Management System Certification‌.

November:‌ Re-recognized as a ‌High-Tech Enterprise‌.

September:‌ Awarded the title of ‌Innovative Enterprise in the 1st GBA Biotech Innovation 50‌.

‌June:‌ ‌DiQi Laboratories successfully passed an independent third-party audit and received positive feedback!

May:‌ ‌Acyclovir Tablets‌, developed by DiQi Pharma for a client company, ‌successfully received FDA approval‌, marking DiQi's first technical service project approved by the FDA!

‌April:‌ Rated as a ‌Class A Taxpayer for Tax Credit in 2017‌ by the Guangzhou National and Local Taxation Bureaus.

‌December:‌ Recognized as a ‌2017 Guangzhou Development District Gazelle Enterprise‌.

November:‌ Awarded the title of ‌"2017 Guangzhou Development District Best Talent Employer"‌.

September:‌ Recognized as the ‌Guangdong Provincial Engineering Technology Research Center for Generic Drug Consistency Evaluation‌.

June:‌ Recognized as ‌Guangzhou DiQi's Generic and Innovative Drug R&D and Consulting Service Institution‌.

‌March:‌ Recognized as a ‌2016 Guangzhou Development District Gazelle Enterprise.

December:‌ Received the ‌Outstanding Enterprise Award‌ at the ‌5th China Innovation and Entrepreneurship Competition (National Finals)‌.

October:‌ ‌Cefaclor Sustained-Release Tablets‌ obtained ‌clinical approval‌, marking DiQi's first collaborative project to receive a clinical approval.

September:‌ Recognized as a ‌2015 Guangzhou Municipal Enterprise R&D Institution‌.

May:‌ Recognized as ‌Guangdong Province's Sixth Batch Postdoctoral Innovation Practice Base‌.

January:‌ Recognized as a ‌2015 Guangzhou Development District Gazelle Enterprise‌.

October:‌ Recognized as a ‌High-Tech Enterprise‌ for the ‌first‌ time.

October:‌ Underwent its ‌first on-site inspection by the National Medical Products Administration (NMPA) and passed successfully‌.

December:‌ Won the ‌Third Prize‌ at the ‌3rd China Innovation and Entrepreneurship Competition (Guangdong Division) & 2nd "Pearl River Angel Cup" Sci-Tech Innovation and Entrepreneurship Competition‌.

September:‌ Received the ‌Outstanding Enterprise Award‌ at the ‌3rd China Innovation and Entrepreneurship Competition (National Finals)‌.

‌July:‌ Became one of the ‌first enterprises to sign and settle‌ upon the opening of ‌Guangzhou International Bio Island.

June:‌ Relocated its address to the ‌China National Analytical Center Guangzhou (CNACG) building‌.

January 31st:‌ ‌Company founded‌.